Cargando…
Human APOBEC3B promotes tumor heterogeneity in vivo including signature mutations and metastases
The antiviral DNA cytosine deaminase APOBEC3B has been implicated as a source of mutation in many different cancers. Despite over 10 years of work, a causal relationship has yet to be established between APOBEC3B and any stage of carcinogenesis. Here we report a murine model that expresses tumor-lik...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980288/ https://www.ncbi.nlm.nih.gov/pubmed/36865194 http://dx.doi.org/10.1101/2023.02.24.529970 |
_version_ | 1784899884152782848 |
---|---|
author | Durfee, Cameron Temiz, Nuri Alpay Levin-Klein, Rena Argyris, Prokopios P. Alsøe, Lene Carracedo, Sergio de la Vega, Alicia Alonso Proehl, Joshua Holzhauer, Anna M. Seeman, Zachary J. Lin, Yu-Hsiu T. Vogel, Rachel I. Sotillo, Rocio Nilsen, Hilde Harris, Reuben S. |
author_facet | Durfee, Cameron Temiz, Nuri Alpay Levin-Klein, Rena Argyris, Prokopios P. Alsøe, Lene Carracedo, Sergio de la Vega, Alicia Alonso Proehl, Joshua Holzhauer, Anna M. Seeman, Zachary J. Lin, Yu-Hsiu T. Vogel, Rachel I. Sotillo, Rocio Nilsen, Hilde Harris, Reuben S. |
author_sort | Durfee, Cameron |
collection | PubMed |
description | The antiviral DNA cytosine deaminase APOBEC3B has been implicated as a source of mutation in many different cancers. Despite over 10 years of work, a causal relationship has yet to be established between APOBEC3B and any stage of carcinogenesis. Here we report a murine model that expresses tumor-like levels of human APOBEC3B after Cre-mediated recombination. Animals appear to develop normally with full-body expression of APOBEC3B. However, adult males manifest infertility and older animals of both sexes show accelerated rates of tumorigenesis (mostly lymphomas or hepatocellular carcinomas). Interestingly, primary tumors also show overt heterogeneity, and a subset spreads to secondary sites. Both primary and metastatic tumors exhibit increased frequencies of C-to-T mutations in TC dinucleotide motifs consistent with the established biochemical activity of APOBEC3B. Elevated levels of structural variation and insertion-deletion mutations also accumulate in these tumors. Together, these studies provide the first cause-and-effect demonstration that human APOBEC3B is an oncoprotein capable of causing a wide range of genetic changes and driving tumor formation in vivo. |
format | Online Article Text |
id | pubmed-9980288 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-99802882023-03-03 Human APOBEC3B promotes tumor heterogeneity in vivo including signature mutations and metastases Durfee, Cameron Temiz, Nuri Alpay Levin-Klein, Rena Argyris, Prokopios P. Alsøe, Lene Carracedo, Sergio de la Vega, Alicia Alonso Proehl, Joshua Holzhauer, Anna M. Seeman, Zachary J. Lin, Yu-Hsiu T. Vogel, Rachel I. Sotillo, Rocio Nilsen, Hilde Harris, Reuben S. bioRxiv Article The antiviral DNA cytosine deaminase APOBEC3B has been implicated as a source of mutation in many different cancers. Despite over 10 years of work, a causal relationship has yet to be established between APOBEC3B and any stage of carcinogenesis. Here we report a murine model that expresses tumor-like levels of human APOBEC3B after Cre-mediated recombination. Animals appear to develop normally with full-body expression of APOBEC3B. However, adult males manifest infertility and older animals of both sexes show accelerated rates of tumorigenesis (mostly lymphomas or hepatocellular carcinomas). Interestingly, primary tumors also show overt heterogeneity, and a subset spreads to secondary sites. Both primary and metastatic tumors exhibit increased frequencies of C-to-T mutations in TC dinucleotide motifs consistent with the established biochemical activity of APOBEC3B. Elevated levels of structural variation and insertion-deletion mutations also accumulate in these tumors. Together, these studies provide the first cause-and-effect demonstration that human APOBEC3B is an oncoprotein capable of causing a wide range of genetic changes and driving tumor formation in vivo. Cold Spring Harbor Laboratory 2023-02-25 /pmc/articles/PMC9980288/ /pubmed/36865194 http://dx.doi.org/10.1101/2023.02.24.529970 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. |
spellingShingle | Article Durfee, Cameron Temiz, Nuri Alpay Levin-Klein, Rena Argyris, Prokopios P. Alsøe, Lene Carracedo, Sergio de la Vega, Alicia Alonso Proehl, Joshua Holzhauer, Anna M. Seeman, Zachary J. Lin, Yu-Hsiu T. Vogel, Rachel I. Sotillo, Rocio Nilsen, Hilde Harris, Reuben S. Human APOBEC3B promotes tumor heterogeneity in vivo including signature mutations and metastases |
title | Human APOBEC3B promotes tumor heterogeneity in vivo including signature mutations and metastases |
title_full | Human APOBEC3B promotes tumor heterogeneity in vivo including signature mutations and metastases |
title_fullStr | Human APOBEC3B promotes tumor heterogeneity in vivo including signature mutations and metastases |
title_full_unstemmed | Human APOBEC3B promotes tumor heterogeneity in vivo including signature mutations and metastases |
title_short | Human APOBEC3B promotes tumor heterogeneity in vivo including signature mutations and metastases |
title_sort | human apobec3b promotes tumor heterogeneity in vivo including signature mutations and metastases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980288/ https://www.ncbi.nlm.nih.gov/pubmed/36865194 http://dx.doi.org/10.1101/2023.02.24.529970 |
work_keys_str_mv | AT durfeecameron humanapobec3bpromotestumorheterogeneityinvivoincludingsignaturemutationsandmetastases AT temiznurialpay humanapobec3bpromotestumorheterogeneityinvivoincludingsignaturemutationsandmetastases AT levinkleinrena humanapobec3bpromotestumorheterogeneityinvivoincludingsignaturemutationsandmetastases AT argyrisprokopiosp humanapobec3bpromotestumorheterogeneityinvivoincludingsignaturemutationsandmetastases AT alsøelene humanapobec3bpromotestumorheterogeneityinvivoincludingsignaturemutationsandmetastases AT carracedosergio humanapobec3bpromotestumorheterogeneityinvivoincludingsignaturemutationsandmetastases AT delavegaaliciaalonso humanapobec3bpromotestumorheterogeneityinvivoincludingsignaturemutationsandmetastases AT proehljoshua humanapobec3bpromotestumorheterogeneityinvivoincludingsignaturemutationsandmetastases AT holzhauerannam humanapobec3bpromotestumorheterogeneityinvivoincludingsignaturemutationsandmetastases AT seemanzacharyj humanapobec3bpromotestumorheterogeneityinvivoincludingsignaturemutationsandmetastases AT linyuhsiut humanapobec3bpromotestumorheterogeneityinvivoincludingsignaturemutationsandmetastases AT vogelracheli humanapobec3bpromotestumorheterogeneityinvivoincludingsignaturemutationsandmetastases AT sotillorocio humanapobec3bpromotestumorheterogeneityinvivoincludingsignaturemutationsandmetastases AT nilsenhilde humanapobec3bpromotestumorheterogeneityinvivoincludingsignaturemutationsandmetastases AT harrisreubens humanapobec3bpromotestumorheterogeneityinvivoincludingsignaturemutationsandmetastases |